Cycurion Seeks Shareholder Approval for Highly Dilutive Warrant Exercise to Unlock $12M Capital

summarizeSummary

Cycurion, Inc. is seeking shareholder approval for the potential issuance of up to 3.3 million shares from warrant exercises, representing approximately 79% dilution, to unlock up to $12 million in critical funding from a December 2025 private placement.

check_boxKey Events · Financing and Capital Events · CYCU

• Shareholder Vote on Warrant Exercise

  Cycurion, Inc. will hold a special meeting on February 26, 2026, to seek shareholder approval for the issuance of up to 3,314,920 shares of common stock upon the exercise of warrants.

• Significant Potential Dilution

  The potential issuance of 3,314,920 shares represents approximately 79% of the company's currently outstanding common stock, which is a substantial dilutive event for existing shareholders.

• Critical Capital Infusion

  Approval would enable the company to receive up to $12 million in gross proceeds if all warrants are exercised for cash, which is vital for funding operations and avoiding adverse impacts on the company's financial runway.

• Warrant Pricing Above Current Market

  The warrants have an initial exercise price of $3.62 per share, which is above the current stock price of $2.48, indicating the private placement was priced at a premium.

auto_awesomeAnalysis · CYCU · Technology

This preliminary proxy statement details a critical shareholder vote for Cycurion, Inc. to approve the issuance of shares upon the exercise of warrants from a December 2025 private placement. The approval is necessary to comply with Nasdaq listing rules, as the potential issuance of 3.3 million shares represents approximately 79% of the company's currently outstanding common stock. While this level of dilution is substantial and could negatively impact existing shareholders and the stock price, the approval would enable the company to receive up to $12 million in gross proceeds if the warrants are exercised for cash. For a company with a market capitalization of less than $10 million, this capital infusion is vital for funding operations and avoiding adverse impacts. The warrants' exercise price of $3.62 per share is notably above the current stock price of $2.48, indicating that the original private placement was priced at a premium. The market will closely watch the outcome of this vote, as it directly impacts the company's financial runway and the future value of its shares.